These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24521156)

  • 21. Identification of a new series of amides as non-covalent proteasome inhibitors.
    Scarbaci K; Troiano V; Micale N; Ettari R; Tamborini L; Di Giovanni C; Cerchia C; Grasso S; Novellino E; Schirmeister T; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Apr; 76():1-9. PubMed ID: 24561716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophore modeling technique applied for the discovery of proteasome inhibitors.
    Pautasso C; Troia R; Genuardi M; Palumbo A
    Expert Opin Drug Discov; 2014 Aug; 9(8):931-43. PubMed ID: 24877566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the 26S proteasome by peptide mimics of the coiled-coil region of its ATPase subunits.
    Inobe T; Genmei R
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):143-50. PubMed ID: 26522225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A panel of subunit-selective activity-based proteasome probes.
    Verdoes M; Willems LI; van der Linden WA; Duivenvoorden BA; van der Marel GA; Florea BI; Kisselev AF; Overkleeft HS
    Org Biomol Chem; 2010 Jun; 8(12):2719-27. PubMed ID: 20449511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indolo-phakellins as β5-specific noncovalent proteasome inhibitors.
    Beck P; Lansdell TA; Hewlett NM; Tepe JJ; Groll M
    Angew Chem Int Ed Engl; 2015 Feb; 54(9):2830-3. PubMed ID: 25581903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
    Totaro KA; Barthelme D; Simpson PT; Jiang X; Lin G; Nathan CF; Sauer RT; Sello JK
    ACS Infect Dis; 2017 Feb; 3(2):176-181. PubMed ID: 28183185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor.
    Hasegawa M; Yasuda Y; Tanaka M; Nakata K; Umeda E; Wang Y; Watanabe C; Uetake S; Kunoh T; Shionyu M; Sasaki R; Shiina I; Mizukami T
    Eur J Med Chem; 2014 Jan; 71():290-305. PubMed ID: 24321833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Support vector machine based prediction of P. falciparum proteasome inhibitors and development of focused library by molecular docking.
    Subramaniam S; Mehrotra M; Gupta D
    Comb Chem High Throughput Screen; 2011 Dec; 14(10):898-907. PubMed ID: 21843142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
    Xu K; Wang K; Yang Y; Yan DA; Huang L; Chen CH; Xiao Z
    Eur J Med Chem; 2015 Jun; 98():61-8. PubMed ID: 26005024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.
    Guedes RA; Serra P; Salvador JA; Guedes RC
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition.
    Nickeleit I; Zender S; Sasse F; Geffers R; Brandes G; Sörensen I; Steinmetz H; Kubicka S; Carlomagno T; Menche D; Gütgemann I; Buer J; Gossler A; Manns MP; Kalesse M; Frank R; Malek NP
    Cancer Cell; 2008 Jul; 14(1):23-35. PubMed ID: 18598941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
    Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling.
    Stauch B; Simon B; Basile T; Schneider G; Malek NP; Kalesse M; Carlomagno T
    Angew Chem Int Ed Engl; 2010 May; 49(23):3934-8. PubMed ID: 20408152
    [No Abstract]   [Full Text] [Related]  

  • 34. Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides.
    Artschwager R; Ward DJ; Gannon S; Brouwer AJ; van de Langemheen H; Kowalski H; Liskamp RMJ
    J Med Chem; 2018 Jun; 61(12):5395-5411. PubMed ID: 29782167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concise Chemoenzymatic Total Synthesis and Identification of Cellular Targets of Cepafungin I.
    Amatuni A; Shuster A; Adibekian A; Renata H
    Cell Chem Biol; 2020 Oct; 27(10):1318-1326.e18. PubMed ID: 32763140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors.
    Cheemanapalli S; Anuradha CM; Madhusudhana P; Mahesh M; Raghavendra PB; Kumar CS
    Anticancer Agents Med Chem; 2016; 16(11):1496-1510. PubMed ID: 27173965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular modeling on porphyrin derivatives as β5 subunit inhibitor of 20S proteasome.
    Arba M; Nur-Hidayat A; Ruslin ; Yusuf M; Sumarlin ; Hertadi R; Wahyudi ST; Surantaadmaja SI; Tjahjono DH
    Comput Biol Chem; 2018 Jun; 74():230-238. PubMed ID: 29674291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
    Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
    ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome.
    Groll M; Götz M; Kaiser M; Weyher E; Moroder L
    Chem Biol; 2006 Jun; 13(6):607-14. PubMed ID: 16793518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.